KPRX
Income statement / Annual
Last year (2025), Kiora Pharmaceuticals Inc's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, Kiora Pharmaceuticals Inc's net income was -$10.84 M.
See Kiora Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$16.00 M |
$0.00 |
$0.00 |
$0.00 |
$12.06 K |
$2.69 M |
$1.65 M |
$407.52 K |
$669.26 K |
| Cost of Revenue |
$24.80 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.27 M
|
$4.89 K
|
$8.06 M
|
$10.33 M
|
$8.42 M
|
| Gross Profit |
-$24.80 K
|
$16.00 M
|
$0.00
|
$0.00
|
$0.00
|
-$3.26 M
|
$2.68 M
|
-$6.40 M
|
-$9.92 M
|
-$7.75 M
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
0
|
-270.39
|
1
|
-3.87
|
-24.35
|
-11.58
|
| Research and Development Expenses |
$10.78 M
|
$4.90 M
|
$4.03 M
|
$3.45 M
|
$5.35 M
|
$3.57 M
|
$5.39 M
|
$8.06 M
|
$10.33 M
|
$8.42 M
|
| General & Administrative Expenses |
$5.75 M
|
$5.54 M
|
$4.66 M
|
$8.28 M
|
$5.32 M
|
$4.24 M
|
$4.41 M
|
$4.44 M
|
$4.64 M
|
$5.59 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.75 M
|
$5.54 M
|
$4.66 M
|
$8.28 M
|
$5.32 M
|
$4.24 M
|
$4.41 M
|
$4.44 M
|
$4.64 M
|
$5.59 M
|
| Other Expenses |
-$7.09 M
|
$1.05 M
|
$3.90 M
|
$582.61 K
|
$3.56 M
|
-$4.20 M
|
$0.00
|
$0.00
|
$4.64 M
|
$0.00
|
| Operating Expenses |
$9.43 M
|
$11.49 M
|
$12.59 M
|
$12.31 M
|
$14.24 M
|
$3.61 M
|
$9.80 M
|
$12.50 M
|
$14.97 M
|
$14.02 M
|
| Cost And Expenses |
$9.46 M
|
$11.49 M
|
$12.59 M
|
$12.31 M
|
$14.24 M
|
$6.88 M
|
$9.80 M
|
$12.50 M
|
$14.97 M
|
$14.02 M
|
| Interest Income |
$894.00 K
|
$1.25 M
|
$173.99 K
|
$56.89 K
|
$1.14 K
|
$23.34 K
|
$108.07 K
|
$120.36 K
|
$564.00
|
$3.68 K
|
| Interest Expense |
$19.96 K
|
$21.45 K
|
$11.13 K
|
$8.60 K
|
$6.85 K
|
$4.19 K
|
$325.00
|
$1.04 K
|
$1.22 K
|
$275.00
|
| Depreciation & Amortization |
$24.80 K
|
$19.21 K
|
$51.80 K
|
$41.61 K
|
$45.30 K
|
$33.40 K
|
$213.93 K
|
$38.48 K
|
$19.29 K
|
$5.19 K
|
| EBITDA |
-$12.07 M |
$5.70 M |
-$12.36 M |
-$13.65 M |
-$13.91 M |
-$7.47 M |
-$6.79 M |
-$10.69 M |
-$14.54 M |
-$13.34 M |
| EBITDA Ratio |
0
|
0.36
|
0
|
0
|
0
|
-619.62
|
-2.53
|
-6.47
|
-35.68
|
-19.93
|
| Operating Income Ratio |
0
|
0.28
|
0
|
0
|
0
|
-569.61
|
-2.61
|
-6.56
|
-35.73
|
-19.94
|
| Total Other Income/Expenses Net |
-$2.66 M
|
$1.15 M
|
$163.32 K
|
-$1.39 M
|
$272.48 K
|
$19.15 K
|
$107.74 K
|
$119.32 K
|
-$91.71 K
|
$3.41 K
|
| Income Before Tax |
-$12.12 M
|
$5.66 M
|
-$12.42 M
|
-$13.70 M
|
-$13.96 M
|
-$6.85 M
|
-$7.00 M
|
-$10.73 M
|
-$14.56 M
|
-$13.34 M
|
| Income Before Tax Ratio |
0
|
0.35
|
0
|
0
|
0
|
-568.02
|
-2.61
|
-6.49
|
-35.73
|
-19.94
|
| Income Tax Expense |
-$1.28 M
|
$2.07 M
|
$90.32 K
|
-$113.01 K
|
-$192.60 K
|
$12.06 K
|
$95.40 K
|
$86.05 K
|
-$1.34 M
|
$3.68 K
|
| Net Income |
-$10.84 M
|
$3.59 M
|
-$12.51 M
|
-$13.58 M
|
-$13.77 M
|
-$6.86 M
|
-$7.10 M
|
-$10.81 M
|
-$13.22 M
|
-$13.34 M
|
| Net Income Ratio |
0
|
0.22
|
0
|
0
|
0
|
-569.02
|
-2.64
|
-6.54
|
-32.44
|
-19.94
|
| EPS |
-2.6 |
0.93 |
-24.25 |
-18.55 |
-68 |
-70.5 |
-89.24 |
-182.81 |
-556.17 |
-906.3 |
| EPS Diluted |
-2.64 |
0.87 |
-24.25 |
-18.55 |
-68 |
-70.5 |
-89.24 |
-182.81 |
-556.17 |
-906.3 |
| Weighted Average Shares Out |
$4.17 M
|
$3.87 M
|
$538.01 K
|
$732.30 K
|
$241.10 K
|
$114.79 K
|
$79.53 K
|
$59.14 K
|
$23.77 K
|
$14.72 K
|
| Weighted Average Shares Out Diluted |
$4.10 M
|
$4.13 M
|
$538.01 K
|
$732.30 K
|
$241.10 K
|
$114.79 K
|
$79.53 K
|
$59.14 K
|
$23.77 K
|
$14.72 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
